Jianfeng Group Lin2016 -029 (Announcement on Progress of Subsidiary's Foreign Investment)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Pro 2016-029
Bond Abbreviation: 13 Peak 01 Bond Code: 122227
Bond Abbreviation: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Progress of Subsidiary's Foreign Investment
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Basic Information on Foreign Investment in 1.
On July 12, 2016 , Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), a subsidiary of the Company, and Germany Gefu Pharmaceutical Co., Ltd. (hereinafter referred to as "Gefu Pharmaceutical"), Zhuhai Hengqin Deyunjia International Trade Co., Ltd. (hereinafter referred to: de Yunjia) signed the "Sino-foreign Joint Venture Contract" and jointly funded the establishment of a Sino-foreign joint venture in Jinhua City, Zhejiang Province, China, committed to building a pharmaceutical company for infants and children. The Chinese name of the joint venture company is: Zhejiang Jindel Baby Pharmaceutical Co., Ltd. The registered capital of the joint venture company is RMB 20 million, of which: Jianfeng Pharmaceutical contributed RMB 11 million in cash, Ge Fu Pharmaceutical contributed RMB 5 million in the evaluation of intellectual property rights of proprietary technology, and Deyunjia contributed RMB 4 million in cash.
For details, please refer to 2016 -Lin 2016-026 "Announcement on Foreign Investment of Subsidiaries" published by the company in the designated information disclosure media "shanghai securities news", "china securities journal" and the website of Shanghai Stock Exchange (www.sse.com.cn ) on July 13, 40.
Progress of 2. Foreign InvestmentAfter the signing of the Sino-Foreign Joint Venture Contract, the parties to the cooperation have applied to the relevant departments in accordance with relevant national laws, regulations and relevant government regulations and obtained the Approval Certificate for the People's Republic of China Foreign-invested Enterprises and the Business License.
The main registration items of the "Business License" are as follows:
Name: Zhejiang Jindel Baby Drug Co., Ltd.
Unified Social Credit Code: 91330700MA28E8DU4L
Type: Limited Liability Company (
Sino-foreign Joint Venture)
Domicile: legal Representative of, 3rd Floor, X02 Office Quality Inspection Building, No. 58
, Gaofan Section, Tangxi Town, Wucheng District, Jinhua City, Zhejiang Province: Jiang XiaomengRegistered Capital: RMB 20 Million Yuan
Date of Establishment: August 30, 2016
Business Term: 2016
from August 30 to August 29, 2046
Scope of business: drug research and development, drug production (see "Drug Production License" for the specific scope), drug business (see "Drug Business License" for the specific scope), import and export of health products. (For projects subject to approval according to law, business activities can only be carried out after approval by relevant departments)As of the date of this announcement, the cooperating parties have not yet made capital contributions.
3. Reference Document
Copy of Business License of Zhejiang Jindal Baby Pharmaceutical Co., Ltd. and Approval Certificate of the People's Republic of China Foreign Investment Enterprise.
hereby announce
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
September 2, 2016
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page